Research Library

In a new brief, contributing expert Robert Barron explores the first phase of the Israel-Hamas war and what stakeholders must consider for a viable pathway to peace.

This policy brief explores the dangerous potential of neuroweapons, the need for a “Neuroshield” to protect democracies from the risks of disinformation, the implications of brain-computer interfaces and other national security considerations related to brain health.

This brief demonstrates that the stories and voices of people on the move should be noticed and reflected, and that people on the move should have a leading say regarding the contexts and conditions that affect them, as well as how they are represented.

Visiting scholar Osamah Alsayegh explores the water and energy challenges of GCC states and offers three key policy recommendations that could help to build the region’s resilience and sustainability.

As the judicial battle over Texas Gov. Greg Abbott’s ban on mask mandates continues, the authors argue that the most effective way to protect children from COVID-19 is to require masks in schools. Click below for their full list of policy recommendations, including what exceptions should be made, and when and how to end school mask requirements.

A pending bill in Congress would hobble OPEC by opening the door to anti-trust lawsuits against government-owned oil companies. This brief examines the multiple ways such legislation, known as NOPEC, would undermine critical U.S. interests. DOI: https://doi.org/10.25611/rezh-fc53

Fellows Gabriel Collins and Jim Krane argue in this issue brief that despite changes in U.S.-Persian Gulf trade relations, the U.S. retains an enduring interest in preserving political stability and securing oil flows from the region.

Despite many differences, the United States and Saudi Arabia maintain important mutual interests. Fellow Jim Krane explains why rebuilding ties with Saudi Arabia could incentivize the kingdom to place more importance on U.S. goals.

The human papillomavirus (HPV) affects over 80 million Americans, causing more than 40,000 cases of HPV-associated cancers in the U.S. In 2006, the FDA licensed the first HPV vaccine, which could help save thousands of lives; no cure for HPV currently exists. However, the political controversy raised by the vaccine has limited its acceptance and use. Such resistance potentially jeopardizes an opportunity to reduce cancer rates in Texas and the broader United States.